slides · global inventory
Paragraph
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 118,471
Current window 99,301-99,330
Pages 3,950
Rows per page 30
Component
99,301-99,330 of 118,471
11
Slide highlights a strategic partnership/supply agreement as a form of business traction.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Loop · Pattern Hunter1 hit
13
The slide outlines a clinical trial process flow including randomization and expansion phases.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Loop · Pattern Hunter1 hit
18
DCR = Disease Control Rate. Data presented in three separate tables for different dose cohorts.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
23
The slide outlines a multi-stage clinical trial design (Part A/B to Part C) involving immune activation with various checkpoint inhibitors.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
25
The table compares three treatment regimens across four categories: Expected Efficacy, Safety Profile, Administration, and Trial of Reference.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
26
The table compares historical standard of care data against planned THIO-102 trial outcomes.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
27
MAIA Biotechnology | Investor Presentation Deck | 39 slidesMAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
31
The slide outlines a clinical trial process flow from initial baskets through immune activation to a pivotal phase.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
36
The chart compares the $42B combined market of major CPIs against a $0.5B figure, likely representing the company's specific asset or segment.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Market Size1 hit
39
The slide serves as a milestone marker for the company's public listing.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
01
Mainz Biomed NV | Investor Presentation Deck | 27 slidesMainz Biomed NV | Investor Presentation Deck | 27 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
06
Includes a process diagram for the test workflow and product imagery.Mainz Biomed NV | Investor Presentation Deck | 27 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
08
The slide presents clinical validation data for the ColoAlert diagnostic test.Mainz Biomed NV | Investor Presentation Deck | 27 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
11
Uses a visual timeline/process flow to explain the biological progression of CRC.Mainz Biomed NV | Investor Presentation Deck | 27 slides · Mainz Biomed
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
17
Includes a highlighted box emphasizing the performance of the DNA+mRNA+FIT test for CRC and AA.Mainz Biomed NV | Investor Presentation Deck | 27 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
20
Includes a legend for commercial launch stars and mentions future feasibility studies for other tests.Mainz Biomed NV | Investor Presentation Deck | 27 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
23
The slide uses a grid layout to present 10 advisors with headshots, titles, and company logos.Mainz Biomed NV | Investor Presentation Deck | 27 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
01
Mainz Biomed NV | Investor Presentation Deck | 28 slidesMainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
06
Includes a process diagram for the test workflow and product imagery.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations Beat · Product1 hit
08
The slide presents clinical validation data for the ColoAlert diagnostic test.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
11
Uses a visual timeline/process flow to explain the disease progression.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
12
AA = Advanced Adenoma; CRC = Colorectal Cancer. Data sourced from JNCI 2022.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
18
Includes a highlighted box emphasizing the primary performance metrics for CRC and AA detection.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
24
The slide uses a grid layout to present 10 key advisors with headshots, titles, and company logos.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
26
Includes unaudited financial results and balance sheet data.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
01
Matson | Results Presentation Deck | 10 slidesMatson | Results Presentation Deck | 10 slides · Matson
Conference presentation Investor relations 1 hit
01
Matson | Results Presentation Deck | 18 slidesMatson | Results Presentation Deck | 18 slides · Matson
Conference presentation Investor relations Beat · Attention1 hit
18
Includes two separate tables for three-month and nine-month periods.Matson | Results Presentation Deck | 18 slides · Matson
Conference presentation Investor relations Beat · Action1 hit
01
MaxCyte | Investor Presentation Deck | 19 slidesMaxCyte | Investor Presentation Deck | 19 slides · MaxCyte
Pitch deck Investor relations 1 hit
06
The chart shows a cumulative growth of partnerships over time from 2017 to 2023.MaxCyte | Investor Presentation Deck | 19 slides · MaxCyte
Pitch deck Investor relations Beat · Traction1 hit